Such changes may regulate MICALs’ effects in vivo – particularly given that intracellular alkaline pH promotes tumor progression and growth (White et al., 2017), and H+ transporters NBCn1 and NHE1 (and thereby intracellular alkaline pH) are upregulated in specific cancers [e.g., (Flinck et al., 2018)], and increased MICAL activity is associated with specific cancers (Yoon and Terman, 2018b) (see below). Here, SLC9A1 is linked to cancer.